Stoke Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
10-K: Stoke Therapeutics Reports 2024 Results, Highlights Progress in Dravet Syndrome and ADOA Programs
Stoke Therapeutics' 10-K filing summarizes the company's financial results for 2024 and provides updates on its clinical development programs, including zorevunersen for Dravet syndrome and STK-002 for Autosomal Dominant Optic Atrophy (ADOA).
NASDAQ
Stoke Therapeutics provides a detailed overview of its capital stock, anti-takeover provisions, and clinical development programs in its latest 10-K filing.